INTERIM RESULTS FROM a PHASE 1/2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA

Hematological Oncology ◽

10.1002/hon.2437_73 ◽

2017 ◽

Vol 35 ◽

pp. 85-86 ◽

Author(s):

A.F. Herrera ◽

A.J. Moskowitz ◽

N.L. Bartlett ◽

J.M. Vose ◽

R. Ramchandren ◽

...

Keyword(s):

Hodgkin Lymphoma ◽

Phase 1 ◽

Brentuximab Vedotin ◽

Refractory Hodgkin Lymphoma

Download Full-text

Phase 1 trial of brentuximab vedotin in combination with gemcitabine for pediatric and young adult patients with relapsed or refractory Hodgkin lymphoma, a Children’s Oncology Group report.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.8544 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 8544-8544 ◽

Author(s):

Peter D. Cole ◽

Monika Metzger ◽

Richard A. Drachtman ◽

Terzah M. Horton ◽

Xiaowei Liu ◽

...

Keyword(s):

Young Adult ◽

Hodgkin Lymphoma ◽

Phase 1 ◽

Brentuximab Vedotin ◽

Adult Patients ◽

Oncology Group ◽

Phase 1 Trial ◽

Group Report ◽

Refractory Hodgkin Lymphoma

Download Full-text

Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial

The Lancet Haematology ◽

10.1016/s2352-3026(20)30221-0 ◽

2020 ◽

Vol 7 (9) ◽

pp. e660-e670 ◽

Author(s):

Catherine S Diefenbach ◽

Fangxin Hong ◽

Richard F Ambinder ◽

Jonathon B Cohen ◽

Michael J Robertson ◽

...

Keyword(s):

Hodgkin Lymphoma ◽

Phase 1 ◽

Brentuximab Vedotin ◽

Combination Therapies ◽

Multicentre Phase ◽

Refractory Hodgkin Lymphoma

Download Full-text

A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma

Blood ◽

10.1182/blood-2014-12-614636 ◽

2015 ◽

Vol 125 (26) ◽

pp. 4024-4031 ◽

Author(s):

Achim Rothe ◽

Stephanie Sasse ◽

Max S. Topp ◽

Dennis A. Eichenauer ◽

Horst Hummel ◽

...

Keyword(s):

Natural Killer Cells ◽

Natural Killer ◽

Hodgkin Lymphoma ◽

Phase 1 ◽

Brentuximab Vedotin ◽

Phase 1 Study ◽

Killer Cells ◽

New Approach ◽

Refractory Hodgkin Lymphoma

Key Points The bispecific, tetravalent antibody AFM13 represents a new approach engaging natural killer cells via CD16A to fight CD30+ malignancies. AFM13 is well tolerated and active in Hodgkin lymphoma patients who received all standard therapies, including brentuximab vedotin.

Download Full-text

Experience of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma and relapsed/refractory systemic anaplastic large-cell lymphoma in the Named Patient Program: Review of the literature

Critical Reviews in Oncology/Hematology ◽

10.1016/j.critrevonc.2015.03.011 ◽

2015 ◽

Vol 95 (3) ◽

pp. 359-369 ◽

Author(s):

P.L. Zinzani ◽

S. Sasse ◽

J. Radford ◽

O. Shonukan ◽

V. Bonthapally

Keyword(s):

Hodgkin Lymphoma ◽

Anaplastic Large Cell Lymphoma ◽

Cell Lymphoma ◽

Brentuximab Vedotin ◽

Program Review ◽

Review Of The Literature ◽

Large Cell Lymphoma ◽

Refractory Hodgkin Lymphoma

Download Full-text

Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma

Annals of Oncology ◽

10.1093/annonc/mdx791 ◽

2018 ◽

Vol 29 (3) ◽

pp. 724-730 ◽

Author(s):

A.F. Herrera ◽

J. Palmer ◽

P. Martin ◽

S. Armenian ◽

N.-C. Tsai ◽

...

Keyword(s):

Stem Cell ◽

Stem Cell Transplantation ◽

Hodgkin Lymphoma ◽

Cell Transplantation ◽

Autologous Stem Cell Transplantation ◽

Brentuximab Vedotin ◽

Second Line ◽

Refractory Hodgkin Lymphoma

Download Full-text

Treatment patterns and costs of care for patients with relapsed and refractory Hodgkin lymphoma treated with brentuximab vedotin in the United States: A retrospective cohort study

PLoS ONE ◽

10.1371/journal.pone.0180261 ◽

2017 ◽

Vol 12 (10) ◽

pp. e0180261 ◽

Author(s):

Shelagh M. Szabo ◽

Ishan Hirji ◽

Karissa M. Johnston ◽

Ariadna Juarez-Garcia ◽

Joseph M. Connors

Keyword(s):

United States ◽

Cohort Study ◽

Hodgkin Lymphoma ◽

Retrospective Cohort Study ◽

Retrospective Cohort ◽

The United States ◽

Brentuximab Vedotin ◽

Treatment Patterns ◽

Costs Of Care ◽

Refractory Hodgkin Lymphoma

Download Full-text

Successful rapid desensitization to the antibody–drug conjugate brentuximab vedotin in a patient with refractory Hodgkin lymphoma

Journal of Oncology Pharmacy Practice ◽

10.1177/1078155214567164 ◽

2015 ◽

Vol 22 (1) ◽

pp. 188-192 ◽

Author(s):

Marie Fizesan ◽

Christopher Boin ◽

Olivier Aujoulat ◽

Georges Newinger ◽

Dana Ghergus ◽

...

Keyword(s):

Hodgkin Lymphoma ◽

Brentuximab Vedotin ◽

Antibody Drug Conjugate ◽

Drug Conjugate ◽

Refractory Hodgkin Lymphoma ◽

Download Full-text

Brentuximab vedotin and bendamustine: an effective salvage therapy for relapsed or refractory Hodgkin lymphoma patients

Journal of Chemotherapy ◽

10.1080/1120009x.2021.1976912 ◽

2021 ◽

pp. 1-9

Author(s):

Bahar Uncu Ulu ◽

Mehmet Sinan Dal ◽

İpek Yönal Hindilerden ◽

Olga Meltem Akay ◽

Özgür Mehtap ◽

...

Keyword(s):

Hodgkin Lymphoma ◽

Salvage Therapy ◽

Brentuximab Vedotin ◽

Refractory Hodgkin Lymphoma

Download Full-text

Faculty Opinions recommendation of Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.737385075.793581835 ◽

2021 ◽

Author(s):

David Teachey

Keyword(s):

Hodgkin Lymphoma ◽

Salvage Therapy ◽

Brentuximab Vedotin ◽

Refractory Hodgkin Lymphoma

Download Full-text

Brentuximab vedotin as a salvage treatment for relapsed and refractory Hodgkin lymphoma patients in Taiwan

Journal of the Formosan Medical Association ◽

10.1016/j.jfma.2019.07.003 ◽

2019 ◽

Vol 118 (10) ◽

pp. 1466-1470 ◽

Author(s):

Feng-Ming Tien ◽

Cheng-Hong Tsai ◽

Jia-Hau Liu ◽

Chien-Ting Lin

Keyword(s):

Hodgkin Lymphoma ◽

Brentuximab Vedotin ◽

Salvage Treatment ◽

Refractory Hodgkin Lymphoma

Download Full-text